-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 29, Simcere Pharmaceuticals announced that its subsidiary has signed an exclusive license agreement with Kazia Therapeutics, an Australian oncology drug development company, to introduce the anti-cancer drug paxalisib under investigation in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
Paxalisib is a PI3K/mTOR pathway inhibitor with high blood-brain barrier penetration.
According to the agreement, Simcere will be responsible for the development, registration and commercialization of paxalisib in the Greater China region.
Organized from: Simcere Pharmaceutical